{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:58Z","timestamp":1790683858930,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,21]]},"DOI":"10.7759\/cureus.113070","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:26:47Z","timestamp":1784626007000},"source":"Crossref","is-referenced-by-count":1,"title":["O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation-Guided Irinotecan-Based Therapy in Metastatic Colorectal Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Pramod K","family":"Julka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afnan","family":"Bhasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan E","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, et al.. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023, 72:338-44. 10.1136\/gutjnl-2022-327736","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer","volume":"16","author":"Piedbois P","year":"1998","unstructured":"Piedbois P, Rougier P, Buyse M, et al.. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998, 16:301-8. 10.1200\/JCO.1998.16.1.301","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr366","article-title":"Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy","volume":"23","author":"Twelves C","year":"2012","unstructured":"Twelves C, Scheithauer W, McKendrick J, et al.. Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012, 23:1190-7. 10.1093\/annonc\/mdr366","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale","volume":"23","author":"Colucci G","year":"2005","unstructured":"Colucci G, Gebbia V, Paoletti G, et al.. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005, 23:4866-75. 10.1200\/JCO.2005.07.113","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7260.531","article-title":"Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis","volume":"321","author":"Simmonds PC","year":"2000","unstructured":"Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ. 2000, 321:531-5. 10.1136\/bmj.321.7260.531","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham D","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, et al.. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351:337-45. 10.1056\/NEJMoa033025","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le DT","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al.. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015, 372:2509-20. 10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman MJ","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al.. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017, 18:1182-91. 10.1016\/S1470-2045(17)30422-9","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay","volume":"30","author":"Nakamura Y","year":"2024","unstructured":"Nakamura Y, Tsukada Y, Matsuhashi N, et al.. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin Cancer Res. 2024, 30:4377-87. 10.1158\/1078-0432.CCR-24-1651","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00266","article-title":"Toward a molecular classification of colorectal cancer: the role of MGMT","volume":"3","author":"Minoo P","year":"2013","unstructured":"Minoo P. Toward a molecular classification of colorectal cancer: the role of MGMT. Front Oncol. 2013, 3:266. 10.3389\/fonc.2013.00266","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v2.i12.835","article-title":"Role of MGMT as biomarker in colorectal cancer","volume":"2","author":"Inno A","year":"2014","unstructured":"Inno A, Fanetti G, Di Bartolomeo M, et al.. Role of MGMT as biomarker in colorectal cancer. World J Clin Cases. 2014, 2:835-9. 10.12998\/wjcc.v2.i12.835","journal-title":"World J Clin Cases"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2752-9","article-title":"Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review","volume":"36","author":"Li Y","year":"2015","unstructured":"Li Y, Lyu Z, Zhao L, et al.. Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review. Tumour Biol. 2015, 36:1595-601. 10.1007\/s13277-014-2752-9","journal-title":"Tumour Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-5014-1","article-title":"MGMT in colorectal cancer: a promising component of personalized treatment","volume":"37","author":"Zhang L","year":"2016","unstructured":"Zhang L, Zeng J, Zeng Z, et al.. MGMT in colorectal cancer: a promising component of personalized treatment. Tumour Biol. 2016, 37:11443-56. 10.1007\/s13277-016-5014-1","journal-title":"Tumour Biol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.342","article-title":"Apc and p53 interaction in DNA damage and genomic instability in hepatocytes","volume":"34","author":"M\u00e9niel V","year":"2015","unstructured":"M\u00e9niel V, Megges M, Young MA, Cole A, Sansom OJ, Clarke AR. Apc and p53 interaction in DNA damage and genomic instability in hepatocytes. Oncogene. 2015, 34:4118-29. 10.1038\/onc.2014.342","journal-title":"Oncogene"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi ME","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, et al.. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352:997-1003. 10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt547","article-title":"Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation","volume":"25","author":"Pietrantonio F","year":"2014","unstructured":"Pietrantonio F, Perrone F, de Braud F, et al.. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol. 2014, 25:404-8. 10.1093\/annonc\/mdt547","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.109","article-title":"A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation","volume":"116","author":"Calegari MA","year":"2017","unstructured":"Calegari MA, Inno A, Monterisi S, et al.. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br J Cancer. 2017, 116:1279-86. 10.1038\/bjc.2017.109","journal-title":"Br J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3024","article-title":"Capecitabine and temozolomide versus FOLFIRI in RAS-mutated, MGMT-methylated metastatic colorectal cancer","volume":"26","author":"Pietrantonio F","year":"2020","unstructured":"Pietrantonio F, Lobefaro R, Antista M, et al.. Capecitabine and temozolomide versus FOLFIRI in RAS-mutated, MGMT-methylated metastatic colorectal cancer. Clin Cancer Res. 2020, 26:1017-24. 10.1158\/1078-0432.CCR-19-3024","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial","volume":"40","author":"Morano F","year":"2022","unstructured":"Morano F, Raimondi A, Pagani F, et al.. Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial. J Clin Oncol. 2022, 40:1562-73. 10.1200\/JCO.21.02583","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier Y","year":"2006","unstructured":"Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006, 6:789-802. 10.1038\/nrc1977","journal-title":"Nat Rev Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-5916fje","article-title":"Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan\/temozolomide efficacy against colon carcinoma","volume":"20","author":"Tentori L","year":"2006","unstructured":"Tentori L, Leonetti C, Scarsella M, et al.. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan\/temozolomide efficacy against colon carcinoma. FASEB J. 2006, 20:1709-11. 10.1096\/fj.06-5916fje","journal-title":"FASEB J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493250-o6-methylguanine-dna-methyltransferase-mgmt-promoter-methylation-guided-irinotecan-based-therapy-in-metastatic-colorectal-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:26:48Z","timestamp":1784626008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493250-o6-methylguanine-dna-methyltransferase-mgmt-promoter-methylation-guided-irinotecan-based-therapy-in-metastatic-colorectal-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.113070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}